1AD1 Stock Chart & Stats
€14.62
-€0.02(-0.14%)
At close: 4:00 PM EDT
€14.62
-€0.02(-0.14%)
Day’s Range― - ―
52-Week Range€12.24 - €19.01
Previous CloseN/A
Volume0.00
Average Volume (3M)2.00
Market Cap
€1.69B
Enterprise Value€24.54K
Total Cash (Recent Filing)€394.00M
Total Debt (Recent Filing)€5.02B
Price to Earnings (P/E)32.7
Beta0.74
Next Earnings
Oct 21, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.88
Shares Outstanding117,877,460
10 Day Avg. Volume0
30 Day Avg. Volume2
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)3.56
Price to Sales (P/S)1.86
P/FCF Ratio17.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.98Price Target Upside9.33% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.39
Revenue Forecast (FY)€967.36M
Bulls Say, Bears Say
Bulls Say
Sustained Margin ExpansionMargin gains across both business areas, supported by price management and advanced products, indicate improving mix and operating leverage. Management expects margins to remain at the higher level and continue expanding.
Strong Cash GenerationStrong operating and free cash flow improves earnings quality and provides internally generated funding for acquisitions, dividends and investment. This reduces reliance on external financing while supporting AddLife’s consolidation strategy.
Diversified Niche Healthcare PlatformExposure to laboratories, medical technology and home care diversifies demand across healthcare settings. Specialized products, proprietary offerings and recurring customer needs can strengthen retention, margins and cross-selling over time.
Bears Say
Meaningful Balance-Sheet LeverageLeverage has improved but remains material for a medical supplies distributor, limiting financial flexibility if demand weakens or acquisitions require additional funding. Moderate obligation coverage makes continued cash and debt discipline important.
Modest Recent Revenue MomentumRecent top-line growth is limited after stronger earlier expansion, while profitability has not fully returned to prior peak levels. This suggests AddLife still depends on mix, pricing and efficiency gains to sustain earnings growth.
Acquisition Execution DependenceAddLife’s model relies partly on bolt-on acquisitions to expand revenue, products and margins. If deal activity remains below plan, organic growth may carry more of the burden while integration and acquisition costs continue to pressure operating expenses.
AddLife AB News
1AD1 FAQ
What was AddLife AB Class B’s price range in the past 12 months?
AddLife AB Class B lowest stock price was €12.24 and its highest was €19.01 in the past 12 months.
What is AddLife AB Class B’s market cap?
AddLife AB Class B’s market cap is €1.69B.
When is AddLife AB Class B’s upcoming earnings report date?
AddLife AB Class B’s upcoming earnings report date is Oct 21, 2026 which is in 35 days.
How were AddLife AB Class B’s earnings last quarter?
AddLife AB Class B released its earnings results on Jul 16, 2026. The company reported €0.095 earnings per share for the quarter, beating the consensus estimate of €0.094 by €0.002.
Is AddLife AB Class B overvalued?
According to Wall Street analysts AddLife AB Class B’s price is currently Undervalued.
Does AddLife AB Class B pay dividends?
AddLife AB Class B does not currently pay dividends.
What is AddLife AB Class B’s EPS estimate?
AddLife AB Class B’s EPS estimate is 0.08.
How many shares outstanding does AddLife AB Class B have?
AddLife AB Class B has 117,877,460 shares outstanding.
What happened to AddLife AB Class B’s price movement after its last earnings report?
AddLife AB Class B reported an EPS of €0.095 in its last earnings report, beating expectations of €0.094. Following the earnings report the stock price went up 0.947%.
Which hedge fund is a major shareholder of AddLife AB Class B?
Currently, no hedge funds are holding shares in DE:1AD1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AddLife AB Class B
AddLife AB (publ), a company established in 1906 and headquartered in Stockholm, Sweden, specializes in delivering cutting-edge equipment, medical apparatus, and chemical reagents. Its primary clientele includes the healthcare sector, academic and research organizations (such as colleges and universities), and key players within the food and pharmaceutical industries. The firm's operations are divided into two distinct divisions: Labtech and Medtech. The Labtech segment provides a comprehensive array of products, integrated solutions, and expert services, focusing on diagnostics, biomedical research, and general laboratory requirements. This encompasses specialized instruments for areas like haematology, pathology, immediate diagnostic testing (point-of-care), cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, along with consumables and advanced analytical machinery. This division further offers vital support, maintenance, consultancy, and educational programs. Conversely, the Medtech segment concentrates on supplying a wide range of medical devices tailored for critical applications such as surgical procedures, respiratory support, intensive care, wound management, and enteral nutrition. It also develops products for fall prevention, welfare technology, and ear, nose, and throat conditions, in addition to offering specific assistive devices for bathrooms and specialized aids for children with disabilities. AddLife maintains a broad international presence, conducting business in its home country of Sweden, across the Nordics (Finland, Denmark, Norway), the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, other parts of Europe, and globally.
1AD1 Company Deck
1AD1 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasizes broad-based positive operational momentum: margin improvement across both business areas, solid organic growth (4%) augmented by acquisitions (3%), strong Labtech performance (7% currency-adjusted growth), improving cash conversion (~100%) and Home Care emerging as a meaningful growth and margin contributor. Headwinds are mainly timing and market-specific: doctor strikes in Spain, subdued UK capital spending, higher OpEx from growth and acquisitions, inventory timing effects, and increased net debt due to M&A and dividends. Overall, the positives—sustained margin expansion, cash generation and contributing acquisitions—outweigh the transitory market and timing challenges.View all DE:1AD1 earnings summaries1AD1 Stock 12 Month Forecast
Average Price Target
€15.98
▲(9.33% Upside)